Claims for Patent: 7,226,614

Summary for Patent: 7,226,614

Title:	Tablet comprising cetirizine and pseudoephedrine
Abstract:	The present invention concerns a tablet comprising two distinct segments. More particularly, the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.
Inventor(s):	Fanara; Domenico (Wanze, BE), Guichaux; Anthony (Fribourg, CH), Berwaer; Monique (Ham-sur-Heure-Nalinnes, BE), Deleers; Michel (Linkebeek, BE)
Assignee:	UCB Farchim SA (Bulle, CH)
Application Number:	11/251,895
Patent Claims:	1. A method for treating disorders or conditions associated with rhinitis, cold, flu, cold-like and flu like symptoms, and allergic rhinitis, relief of nasal congestion, seasonal rhinitis, rhinorrhea, nasal and ocular pruritus, redness of the eyes, tearing or sneezing which comprises administering a tablet comprising at least two distinct segments, one segment of which comprises as active ingredient predominantly cetirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine, said segments being composed and formed in such a way that the resulting tablet is substantially free of impurities formed by reaction of cetirizine with pseudoephedrine, wherein the interfacial surface area of the pseudoephedrine segment and cetirizine segment is less than 180 mm.sup.2 and with the proviso that the tablet comprises less than 5% by weight, relative to the total weight of the tablet, of an alkalinizing agent to a patient in need of treating said disorders or conditions. 2. A method for treating disorders or conditions associated with rhinitis, cold, flu, cold-like and flu like symptoms, and allergic rhinitis, relief of nasal congestion, seasonal rhinitis, rhinorrhea, nasal and ocular pruritus, redness of the eyes, tearing or sneezing which comprises administering a tablet comprising at least two distinct segments, one segment of which comprises as active ingredient predominantly cetirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine, wherein the interfacial surface area of the pseudoephedrine segment and cetirizine segment is less than 180 mm.sup.2, said segments being composed and formed in such a way that the pharmacokinetic profiles of the cetirizine and pseudoephedrine are substantially the same as in a dosage form containing each as sole active ingredient in the same amount to a patient in need of treating said disorders or conditions.